India API Quality-Inspection Team In China Still Not In Place
This article was originally published in PharmAsia News
India, the target of foreign regulator efforts to ensure the safety of locally produced drugs, has yet to station its own quality-inspection team in China, supplier of much of the raw materials on which India drug makers rely.
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.